Genomic Determinants of Homologous Recombination Deficiency across Human Cancers

SIMPLE SUMMARY: Tumors with homologous recombination deficiency (HRD) respond to Poly-ADP ribose polymerase inhibitor (PARPi) therapy in breast, ovarian, prostate, and pancreatic cancers. However, in addition to a handful of known pathogenic variants including those affecting BRCA1/2, it remains unc...

Descripción completa

Detalles Bibliográficos
Autores principales: Qing, Tao, Wang, Xinfeng, Jun, Tomi, Ding, Li, Pusztai, Lajos, Huang, Kuan-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472123/
https://www.ncbi.nlm.nih.gov/pubmed/34572800
http://dx.doi.org/10.3390/cancers13184572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472123/
https://www.ncbi.nlm.nih.gov/pubmed/34572800
http://dx.doi.org/10.3390/cancers13184572

Ejemplares similares